Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 16, 2025Critical Reviews in Clinical Laboratory SciencesOpen Access

Analytical considerations and clinical utility of plasma phosphorylated Tau217

View Full Paper
Ask AI
Bookmark
Share

Authors

HFHans Frykman

Discussion

Loading...

Member takes

Overview

Analysis shows plasma phosphorylated Tau217 correlates with Alzheimer’s disease pathology, suggesting its use as a biomarker for diagnosis.

Key Points

  • Plasma phosphorylated Tau217 effectively distinguishes Alzheimer's disease from other dementias, improving diagnostic accuracy.
  • Strong association with core Alzheimer's pathology supports plasma phosphorylated Tau217 as a leading biomarker for early detection.
  • Commercial immunoassays have been developed for the measurement of plasma phosphorylated Tau217 in clinical settings.
  • Evaluation of plasma phosphorylated Tau217 is essential for eligibility determination of disease-modifying treatments in Alzheimer's disease.

Cite This Study

Hans Frykman (2025) studied this question.

synapsesocial.com/papers/68d44f7b31b076d99fa56ecdhttps://doi.org/10.1080/10408363.2025.2551648
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease2023 · 259 citations
  2. 2The Metamorphic Nature of the Tau Protein: Dynamic Flexibility Comes at a Cost2016 · 31 citations
  3. 3Alzheimer's disease drug development pipeline: 20212021 · 521 citations
  4. 4Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders2020 · 1,637 citations
  5. 5Phosphorylated Tau in Alzheimer’s Disease and Other Tauopathies2022 · 497 citations